Aeterna Zentaris Announces Appointment of Interim Chief Financial Officer
September 25 2017 - 4:30PM
Business Wire
Aeterna Zentaris Inc. (NASDAQ & TSX: AEZS) a
specialty biopharmaceutical company (the “Company”) announced
effective today, September 25, 2017, that Jeffrey Whitnell has been
appointed to the position of Interim Chief Financial Officer.
Whitnell is an accomplished financial executive with a professional
career spanning approximately 40 years in both large and small
company environments working for various organizations in the life
sciences and biopharmaceutical sectors. Mr. Whitnell brings
extensive background in capital markets and corporate finance
transactions. Most recently, he served as Vice-President, Finance
& Controller of Lifewatch Services, Inc., a publicly traded
medical device company servicing the cardiac monitoring market that
was acquired by BioTelemetry, Inc. in July 2017. From April 2010 to
March 2015, Mr. Whitnell served as Chief Financial Officer and
Controller of Reliefband Medical Technologies, a private
equity-backed medical device company, and from June 2004 to June
2009 Whitnell served as CFO of Akorn, Inc., a then publicly traded
specialty pharma company that was recently acquired by Fresenius
Kabi. Prior to that, Mr. Whitnell held multiple senior finance
positions with various companies, including Ovation
Pharmaceuticals, Medichem Life Sciences, Akzo Nobel and Motorola.
He commenced his professional career as a staff auditor with Arthur
Andersen & Co. Mr. Whitnell has a Bachelor’s of Science degree
in Accountancy from the University of Illinois and a Master’s in
Business Administration from The University of Chicago Booth School
of Business.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel pharmaceutical
therapies. We are engaged in drug development activities and in the
promotion of products for others. We recently resubmitted an NDA to
the FDA seeking approval of MacrilenTM, an internally developed
compound. The focus of our business development efforts is the
acquisition of licenses to products that are relevant to our
therapeutic areas of focus. We also intend to license out certain
commercial rights of internally developed products to licensees in
non-U.S. territories where such out-licensing would enable us to
ensure development, registration and launch of our product
candidates. Our goal is to become a growth-oriented specialty
biopharmaceutical company by pursuing successful development and
commercialization of our product portfolio, achieving successful
commercial presence and growth, while consistently delivering value
to our shareholders, employees and the medical providers and
patients who will benefit from our products. For more information,
visit www.aezsinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170925006423/en/
Aeterna Zentaris Inc.Michael V. WardChief Executive
OfficerIR@aezsinc.com843.900.3223orReilly ConnectSusan
Reillysusan.reilly@reillyconnect.com312.600.6783
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024